```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN
 NEWS 20  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS 21  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS 22  FEB 05   German (DE) application and patent publication number format
                   changes
 NEWS 23  MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS 24  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS 25  MAR 03   FRANCEPAT now available on STN

 NEWS EXPRESS  MARCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
```

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004

=> file medline, uspatful, dgene, embase, wpids, fsta, biosis
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 14:46:40 ON 26 MAR 2004

FILE 'USPATFULL' ENTERED AT 14:46:40 ON 26 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:46:40 ON 26 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 14:46:40 ON 26 MAR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 14:46:40 ON 26 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 14:46:40 ON 26 MAR 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s fluorescent protein and GFP
L1 27483 FLUORESCENT PROTEIN AND GFP

=> s modified GFP and wildtype
L2 16 MODIFIED GFP AND WILDTYPE

=> s l1 and l2
L3 16 L1 AND L2

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 16 USPATFULL on STN
TI Transgenic plants expressing puroindolines and methods for producing such plants
AB This invention relates to plant cells, plant tissues or plants transgenic for a nucleic acid encoding a puroindoline. This invention also relates to methods of producing such transgenic plant cells, plant tissues or plants. The transgenic plants produced by the methods of this invention are useful in reducing the damage caused by plant pests, especially plant pathogens such as fungi and bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:284216 USPATFULL
TITLE: Transgenic plants expressing puroindolines and methods for producing such plants
INVENTOR(S): Giroux, Michael J., Bozeman, MT, UNITED STATES
Sherwood, John, Bozeman, MT, UNITED STATES
Krishnamurthy, K., Rockville, MD, UNITED STATES
Morris, Craig F., Pullman, WA, UNITED STATES

NUMBER	KIND	DATE

PATENT INFORMATION: US 2003200561 A1 20031023
APPLICATION INFO.: US 2003-447541 A1 20030527 (10)
RELATED APPLN. INFO.: Division of Ser. No. US 2000-489674, filed on 24 Jan 2000, GRANTED, Pat. No. US 6600090 Continuation-in-part of Ser. No. US 1998-83852, filed on 22 May 1998, GRANTED, Pat. No. US 6596930
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: USDA-ARS-OFFICE OF TECHNOLOGY TRANSFER, PATENT ADVISORS OFFICE, WESTERN REGIONAL RESEARCH CENTER, 800 BUCHANAN ST, ALBANY, CA, 94710
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 2217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 16 USPATFULL on STN
TI Methods for increasing mRNA half-life in eukaryotic cells
AB A method is provided whereby altered cells exhibit increased intracellular half-life of transcribed mRNAs resulting in increased levels of expressed and/or secreted proteins. The cells are genetically altered to increase the level of intracellular ribosome receptor, which induces mRNA half-life.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:282749 USPATFULL
TITLE: Methods for increasing mRNA half-life in eukaryotic cells
INVENTOR(S): Meyer, David L., Los Angeles, CA, UNITED STATES
PATENT ASSIGNEE(S): The Regents of the University of California (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199092	A1	20031023
APPLICATION INFO.:	US 2003-342136	A1	20030113 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-347533P	20020111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 1839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 16 USPATFULL on STN
TI Better emergence characteristics and improved seedling growth under low-light environments
AB This invention relates to seedlings which demonstrate better emergence characteristics when grown in darkness and improved seedling growth when grown under low-light levels. More specifically, the present invention relates to producing plant cells and whole plants which contain a nucleic acid sequence coding for the Coil domain as well as the sequence coding for the **wildtype** COP1 gene. The plants of this invention display unopened, compact leaves during seedling emergence in the darkness and reduced etiolation of seedings grown in low-levels after emergence. The invention further relates to plant breeding methods which enable the transfer of these desirable traits to **wildtype** plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:233639 USPATFULL
TITLE:	Better emergence characteristics and improved seedling growth under low-light environments
INVENTOR(S):	Deng, Xing Wang, Hamden, CT, UNITED STATES McNellis, Timothy, State College, PA, UNITED STATES Torii, Keiko, Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S):	Yale University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003163841	A1	20030828
APPLICATION INFO.:	US 2003-386499	A1	20030313 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-407956, filed on 28 Sep 1999, GRANTED, Pat. No. US 6579716		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101992P	19980928 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS:	38
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Page(s)
LINE COUNT:	2905

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 16 USPATFULL on STN

TI Transgenic plants expressing puroindolines and methods for producing such plants

AB This invention relates to plant cells, plant tissues or plants transgenic for a nucleic acid encoding a puroindoline. This invention also relates to methods of producing such transgenic plant cells, plant tissues or plants. The transgenic plants produced by the methods of this invention are useful in reducing the damage caused by plant pests, especially plant pathogens such as fungi and bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:203399 USPATFULL
TITLE:	Transgenic plants expressing puroindolines and methods for producing such plants
INVENTOR(S):	Giroux, Michael J., Bozeman, MT, United States Sherwood, John E., Bozeman, MT, United States Krishnamurthy, Krish, Bozeman, MT, United States Morris, Craig F., Pullman, WA, United States
PATENT ASSIGNEE(S):	Montana State University, Bozeman, MT, United States (U.S. corporation) The United States of America as represented by the Secretary of Agriculture, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6600090	B1	20030729
APPLICATION INFO.:	US 2000-489674		20000124 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-83852, filed on 22 May 1998		

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Fox, David T.
ASSISTANT EXAMINER:	Kubelik, Anne

LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 23
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2249
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 16 USPATFULL on STN
TI Better emergence characteristics and improved seedling growth under low-light environments
AB This invention relates to seedlings which demonstrate better emergence characteristics when grown in darkness and improved seedling growth when grown under low-light levels. More specifically, the present invention relates to producing plant cells and whole plants which contain a nucleic acid sequence coding for the Coil domain as well as the sequence coding for the **wildtype** COP1 gene. The plants of this invention display unopened, compact leaves during seedling emergence in the darkness and reduced etiolation of seedlings grown in low-levels after emergence. The invention further relates to plant breeding methods which enable the transfer of these desirable traits to **wildtype** plants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:161889 USPATFULL
TITLE: Better emergence characteristics and improved seedling growth under low-light environments
INVENTOR(S): Deng, Xing Wang, Hamden, CT, United States
McNellis, Timothy, State College, PA, United States
Torii, Keiko, Seattle, WA, United States
PATENT ASSIGNEE(S): Yale University, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6579716	B1	20030617	
APPLICATION INFO.:	US 1999-407956		19990928	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-101992P	19980928	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: McGarry, Sean
ASSISTANT EXAMINER: Zara, Joe
LEGAL REPRESENTATIVE: Morgan, Lewis & Bockius, LLP
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2927
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 16 USPATFULL on STN
TI Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
AB The present invention relates to methods of identifying genes whose expression is indicative of activation of a particular biochemical or metabolic pathway or a common set of biological reactions or functions in a cell ("regulon indicator genes") The present invention provides an example of such an indicator gene. The present invention also relates to methods of partially characterizing a gene of unknown function by determining which biological pathways, reactions or functions its expression is associated with, thereby placing the gene within a functional genetic group or "regulon". These partially characterized genes may be used to identify desirable therapeutic targets of

biological pathways of interest ("regulon target genes") The present invention provides examples of such target genes. Methods for identifying effectors (activators and inhibitors) of regulon target genes are provided. The present invention also provides examples of regulon target gene inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:135137 USPATFULL
TITLE:	Methods for the identification of reporter and target molecules using comprehensive gene expression profiles
INVENTOR(S):	Ashby, Matthew, Mill Valley, CA, UNITED STATES Scherer, Stewart, Moraga, CA, UNITED STATES Phillips, John W., Kirkland, WA, UNITED STATES Ziman, Michael, Seattle, WA, UNITED STATES Marini, Nicholas, San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S):	Rosetta Inpharmatics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003093226	A1	20030515
APPLICATION INFO.:	US 2002-205841	A1	20020726 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-540806, filed on 31 Mar 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-127223P	19990331 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS:	64
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	87 Drawing Page(s)
LINE COUNT:	3369

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 16 USPATFULL on STN

TI Methods for identifying agents that induce a cellular phenotype, and compositions thereof

AB The present invention is directed to methods for performing negative selection assays leading to the identification of cytostatic or cytotoxic agents that cause a lethal phenotype. The invention is useful also for evaluation of conditional cytotoxicity and cell-specific cytotoxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:78469 USPATFULL
TITLE:	Methods for identifying agents that induce a cellular phenotype, and compositions thereof
INVENTOR(S):	Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003054389	A1	20030320
APPLICATION INFO.:	US 2002-196408	A1	20020716 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-309088P	20010731 (60)
	US 2001-305711P	20010716 (60)
	US 2001-305712P	20010716 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: MARSHALL, GERSTEIN & BORUN, 6300 SEARS TOWER, 233 SOUTH WACKER, CHICAGO, IL, 60606-6357
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Page(s)
LINE COUNT: 4473
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 16 USPATFULL on STN
TI Synthetic DNA encoding an orange seapen-derived green **fluorescent protein** with codon preference of mammalian expression systems and biosensors
AB Synthetic versions of a full length and termini truncated humanized green **fluorescent protein** based on Ptilosarcus gurneyi are disclosed which have been modified to the favored or most favored codons for mammalian expression systems. The disclosed encoded protein has 239 amino acid residues compared with the wild type Ptilosarcus gurneyi which has 238 amino acids. In the present invention, a valine residue has been added at the second position from the amino terminus and codon preference bias has been changed in a majority of the wild type codons of Ptilosarcus gurneyi **fluorescent protein**. The humanized Ptilosarcus gurneyi green **fluorescent protein** is useful as a fluorescent tag for monitoring the activities of its fusion partners using imaging based approaches.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:343947 USPATFULL
TITLE: Synthetic DNA encoding an orange seapen-derived green **fluorescent protein** with codon preference of mammalian expression systems and biosensors
INVENTOR(S): Chen, Yih-Tai, Gibsonia, PA, UNITED STATES
Cao, Longguang, Boulder, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002197673	A1	20021226
APPLICATION INFO.:	US 2001-977897	A1	20011015 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-297645P	20010612 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CRAIG G. COCHENOUR, BUCHANAN INGERSOLL, P.C., ONE OXFORD CENTRE, 20th FLOOR, 301 GRANT STREET, PITTSBURGH, PA, 15219
NUMBER OF CLAIMS: 45
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 1714
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 16 USPATFULL on STN
TI Tandem **fluorescent protein** constructs
AB This invention provides tandem **fluorescent protein** construct including a donor **fluorescent protein** moiety, an acceptor **fluorescent protein** moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:294631 USPATFULL
TITLE: Tandem **fluorescent protein** constructs
INVENTOR(S): Tsien, Roger Y., La Jolla, CA, UNITED STATES
Heim, Roger, Del Mar, CA, UNITED STATES
Cubitt, Andrew, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164674	A1	20021107
APPLICATION INFO.:	US 2002-57505	A1	20020125 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-396003, filed on 13 Sep 1999, PENDING Continuation of Ser. No. US 1997-792553, filed on 31 Jan 1997, GRANTED, Pat. No. US 5981200 Continuation-in-part of Ser. No. US 1996-594575, filed on 31 Jan 1996, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 16 USPATFULL on STN
TI Identification of drugs and drug targets by detection of the stress response
AB The invention features methods of high throughput screening of candidate drug agents and rapid identification of drug targets by examining induction of the stress response in a host cell, e.g., the stress response in **wildtype** host cells and/or in host cells that differ in target gene product dosage (e.g., host cells that have two copies of a drug target gene product-encoding sequence relative to one copy). In general, induction of the stress response in **wildtype** host cells indicates that a candidate agent has activity of the drug. Induction of a relatively lower or undetectable stress response in a host cell comprising an alteration in gene product dosage indicates that the host cell is drug-sensitive and is altered in a gene product that plays a role in resistance to the drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:171871 USPATFULL
TITLE: Identification of drugs and drug targets by detection of the stress response
INVENTOR(S): Davis, Ronald W., Palo Alto, CA, UNITED STATES
Giaever, Guri N., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002090620	A1	20020711
APPLICATION INFO.:	US 2001-898745	A1	20010703 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218288P	20000714 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Carol L. Francis, Bozicevic, Field and Francis LLP,

Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1530
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 16 USPATFULL on STN
TI Methods for validating polypeptide targets that correlate to cellular phenotypes
AB Generally applicable methods for identifying physiologically relevant endogenous target molecules, are provided. The methods use both protein interaction assay steps and phenotypic assay steps. In some embodiments, protein interactions are detected utilizing yeast two hybrid techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:85148 USPATFULL
TITLE: Methods for validating polypeptide targets that correlate to cellular phenotypes
INVENTOR(S): Kamb, Carl Alexander, Salt Lake City, UT, UNITED STATES
Caponigro, Giordano Michael, Salt Lake City, UT, UNITED STATES
Teng, David Heng-Fai, Salt Lake City, UT, UNITED STATES
Sandrock, Tanya Marie, Salt Lake City, UT, UNITED STATES
Stump, Mark, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045188	A1	20020418
APPLICATION INFO.:	US 2001-865644	A1	20010525 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-193759, filed on 17 Nov 1998, ABANDONED Continuation-in-part of Ser. No. WO 2001-US9927409, filed on 10 Apr 2001, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Li-Hsien Rin-Laures, MD, MARSHALL, O'TOOLE, GERSTEIN, MURRAY & BORUN, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL, 60606-6402
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2579
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 16 USPATFULL on STN
TI Mutants of the green **fluorescent protein** having improved fluorescent properties at 37°
AB The present invention relates to mutants of the green **fluorescent protein** having improved fluorescent properties at 37° C. The mutants provide for improved methods of monitoring gene expression, e.g., for use as cell markers or protein expression indicators in prokaryotic and, especially, eucaryotic systems where the standard physiological temperature is 37° C.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:98547 USPATFULL
TITLE: Mutants of the green **fluorescent protein** having improved fluorescent properties at 37°
INVENTOR(S): Michaels, Mark, Encino, CA, United States
PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096865		20000801
APPLICATION INFO.:	US 1996-643704		19960506 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Spector, Lorraine
ASSISTANT EXAMINER: Kaufman, Claire M.
LEGAL REPRESENTATIVE: Crandall, Craig A., Levy, Ron K., Odre, Steven M.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 16 USPATFULL on STN
TI Humanized green **fluorescent protein** genes and methods
AB Disclosed are synthetic and "humanized" versions of green **fluorescent protein** (**GFP**) genes adapted for high level expression in mammalian cells, especially those of human origin. Base substitutions are made in various codons in order to change the codon usage to one more appropriate for expression in mammalian cells. Recombinant vectors carrying such humanized genes are also disclosed. In addition, various methods for using the efficient expression of humanized **GFP** in mammalian cells and in animals are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:12655 USPATFULL
TITLE: Humanized green **fluorescent protein** genes and methods
INVENTOR(S): Muzyczka, Nicholas, Gainesville, FL, United States
Zolotukhin, Sergei, Gainesville, FL, United States
Hauswirth, William, Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida, Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020192		20000201
APPLICATION INFO.:	US 1997-893327		19970716 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-588201, filed on 18 Jan 1997
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
ASSISTANT EXAMINER: Wang, Andrew
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 29 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 4342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 16 USPATFULL on STN
TI Tandem **fluorescent protein** constructs
AB This invention provides tandem **fluorescent protein** construct including a donor **fluorescent protein** moiety, an acceptor **fluorescent protein** moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:141607 USPATFULL

TITLE: Tandem **fluorescent protein** constructs

INVENTOR(S): Tsien, Roger Y., La Jolla, CA, United States
Heim, Roger, Del Mar, CA, United States
Cubitt, Andrew, San Diego, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
Aurora Biosciences Corporation, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981200		19991109
APPLICATION INFO.:	US 1997-792553		19970131 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-594575, filed on 31 Jan 1996

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Pak, Michael
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 1903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 16 USPATFULL on STN

TI Humanized green **fluorescent protein** genes and methods

AB Disclosed are synthetic and "humanized" versions of green **fluorescent protein** (**GFP**) genes adapted for high level expression in mammalian cells, especially those of human origin. Base substitutions are made in various codons in order to change the codon usage to one more appropriate for expression in mammalian cells. Recombinant vectors carrying such humanized genes are also disclosed. In addition, various methods for using the efficient expression of humanized **GFP** in mammalian cells and in animals are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:128366 USPATFULL

TITLE: Humanized green **fluorescent protein** genes and methods

INVENTOR(S): Zolotukhin, Sergei, Gainesville, FL, United States
Muzyczka, Nicholas, Gainesville, FL, United States
Hauswirth, William W., Gainesville, FL, United States

PATENT ASSIGNEE(S): The University of Florida Research Foundation Inc., Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5968750		19991019
APPLICATION INFO.:	US 1998-169605		19981009 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-588201, filed on 18 Jan 1996, now patented, Pat. No. US 5874304

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George P.
ASSISTANT EXAMINER: Wang, Andrew
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 30

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 16 USPATFULL on STN
TI Humanized green **fluorescent protein** genes and methods
AB Disclosed are synthetic and "humanized" versions of green **fluorescent protein** (**GFP**) genes adapted for high level expression in mammalian cells, especially those of human origin. Base substitutions are made in various codons in order to change the codon usage to one more appropriate for expression in mammalian cells. Recombinant vectors carrying such humanized genes are also disclosed. In addition, various methods for using the efficient expression of humanized **GFP** in mammalian cells and in animals are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:24523 USPATFULL
TITLE: Humanized green **fluorescent protein** genes and methods
INVENTOR(S): Zolotukhin, Sergei, Gainesville, FL, United States
Muzyczka, Nicholas, Gainesville, FL, United States
Hauswirth, William W., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida Research Foundation, Inc., Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5874304		19990223	
APPLICATION INFO.:	US 1996-588201		19960118	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Degen, Nancy
ASSISTANT EXAMINER: Wang, Andrew
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 81
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 19 Drawing Page(s)
LINE COUNT: 3932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004
L1 27483 S FLUORESCENT PROTEIN AND GFP
L2 16 S MODIFIED GFP AND WILDTYPE
L3 16 S L1 AND L2

=> s l1 and "S175"
L4 51 L1 AND "S175"

=> s l4 and "F64"
L5 4 L4 AND "F64"

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 4 USPATFULL on STN
TI Proteins associated with cell growth, differentiation, and death

AB The invention provides human proteins associated with cell growth, differentiation, and death (CGDD) and polynucleotides which identify and encode CGDD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CGDD.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:282632 USPATFULL

TITLE: Proteins associated with cell growth, differentiation, and death

INVENTOR(S): Azimzai, Yalda, Oakland, CA, UNITED STATES
Au-Young, Janice, Brisbane, CA, UNITED STATES
Batra, Sajeev, Oakland, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Becha, Shanya D., Castro Valley, CA, UNITED STATES
Borowsky, Mark L., Redwood City, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Emerling, Brooke M., Chicago, IL, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Gietzen, Kimberly J., San Jose, CA, UNITED STATES
Griffin, Jennifer A., San Jose, CA, UNITED STATES
Hafalia, April J. A., Santa Clara, CA, UNITED STATES
Honchell, Cynthia D., San Carlos, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Lee, Soo Yeun, Daly City, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Arvizu, Chandra S., San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Reddy, Roopa M., Sunnyvale, CA, UNITED STATES
Sanjanwala, Madhusudan S., Los Altos, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Wang, Yu-Mei E., Mountain View, CA, UNITED STATES
Warren, Bridget A., Encinitas, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Yao, Monique G., Carmel, IN, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Zebarjadian, Yeganeh, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003198975	A1	20031023
APPLICATION INFO.:	US 2002-287218	A1	20021031 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US11152, filed on 5 Apr 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-US11152	20020405
	US 2002-349705P	20020115 (60)
	US 2001-295263P	20010601 (60)
	US 2001-295340P	20010601 (60)
	US 2001-293727P	20010525 (60)
	US 2001-291846P	20010518 (60)
	US 2001-291662P	20010516 (60)
	US 2001-287228P	20010427 (60)
	US 2001-286820P	20010426 (60)
	US 2001-283294P	20010411 (60)
	US 2001-282110P	20010406 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 97
EXEMPLARY CLAIM: 1
LINE COUNT: 10940
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 4 USPATFULL on STN
TI Fluorescent proteins
AB The present invention provides novel engineered derivatives of green **fluorescent protein** (**GFP**) which have an amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild type Green **Fluorescent Protein**. The modified GFPs exhibit enhanced fluorescence relative to wtGFP when expressed in non-homologous cells at temperatures above 30° C., and when excited at about 490 nm compared to the parent proteins, i.e. wtGFP. An example of a preferred protein is F64L-S175G-E222G-**GFP**. The modified GFPs provide a means for detecting **GFP** reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to wtGFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:251073 USPATFULL
TITLE: Fluorescent proteins
INVENTOR(S): Stubbs, Simon Lawrence John, Amersham Buckinghamshire, UNITED KINGDOM
Jones, Anne Elizabeth, Amersham Buckinghamshire, UNITED KINGDOM
Michael, Nigel Paul, Amersham Buckinghamshire, UNITED KINGDOM
Thomas, Nicholas, Amersham Buckinghamshire, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003175859	A1	20030918	
APPLICATION INFO.:	US 2001-967301	A1	20010928	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-9858	20010423

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AMERSHAM BIOSCIENCES, PATENT DEPARTMENT, 800 CENTENNIAL AVENUE, PISCATAWAY, NJ, 08855
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 4 USPATFULL on STN
TI Polynucleotide encoding a novel immunoglobulin superfamily member, APEX4, and variants and splice variants thereof
AB The present invention provides novel polynucleotides encoding APEX4 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of APEX4 polypeptides, APEX4v1 and APEX4sv1, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates

to diagnostic and therapeutic methods for applying these novel APEX4, APEX4v1, and APEX4sv1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:133932 USPATFULL
TITLE:	Polynucleotide encoding a novel immunoglobulin superfamily member, APEX4, and variants and splice variants thereof
INVENTOR(S):	Finger, Joshua N., San Marcos, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003092017	A1	20030515	
APPLICATION INFO.:	US 2002-104943	A1	20020322	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-278037P	20010322	(60)
	US 2001-281223P	20010403	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Page(s)
LINE COUNT:	13219

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 4 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Novel **fluorescent protein** derived from green **fluorescent protein** useful as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type green **fluorescent protein**.

AN 2003-095652 [09] WPIDS

AB GB 2374868 A UPAB: 20030206

NOVELTY - A **fluorescent protein** (I) derived from green **fluorescent protein** (**GFP**) or any functional **GFP** analog, has an amino acid sequence which is modified by amino acid substitution at position **F64**, at position S65 or E222, and at position **S175** compared with the amino acid sequence of wild-type **GFP**, and has different excitation spectrum and/or emission spectrum compared with wild-type **GFP**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a fusion compound (II) comprising a protein of interest fused to (I);

(2) a nucleic acid molecule (III) comprising a nucleotide sequence encoding (I) or (II);

(3) an expression vector (IV) comprising suitable expression control sequences operably linked to (III); and

(4) a host cell (V) transformed or transfected with a DNA construct comprising (IV).

USE - (III) is useful for measuring the expression of a protein of interest in a cell, by introducing (III) into a cell, where (III) is operably linked to and under the control of an expression control sequence which moderates expression of the protein of interest, culturing the cell under conditions suitable for the expression of the protein of interest, and detecting the fluorescence emission of **GFP** or functional **GFP** analog. (III) is useful for determining the cellular and/or

extracellular localization of a protein of interest. (III) is also useful for comparing the effect of one or more test substance(s) on the expression and/or localization of one or more different protein(s) of interest in a cell. The method involves:

(a) introducing into a cell, (III) operably linked to and under the control of a first expression control sequence and optionally fused to a nucleotide sequence encoding a fusion protein of interest, and optionally, at least one different nucleic acid molecule encoding a protein reporter molecule fused to a different protein of interest, where the nucleic acid molecule is operably linked to and under the control of a second expression control sequence, and the protein reporter molecule has or is capable of generating an emission signal which is spectrally distinct from that of **GFP** or functional **GFP** analog;

(b) culturing the cells under conditions suitable for the expression of the protein(s) of interest in the presence and absence of the test substance(s);

(c) determining the expression and/or localization of the protein(s) in the cells by detecting the fluorescence emission by optical means; and

(d) comparing the fluorescence emission obtained in the presence and absence of the test substance(s).

The samples of the cells in a fluid medium are introduced into separate vessels for each of the test substances to be studied (all claimed).

(I) is useful as a non-toxic marker for selection of transfected cells, as a protein label in living and fixed cells, as a marker in cell or organelle fusion, for visualizing translocation of intracellular proteins to a specific organelle, as a secretion marker, as genetic reporter or protein tag for protein and gene expression in transgenic animals, as a cell or organelle integrity marker, as a transfection marker, as a marker to be used in combination with fluorescent activated cell sorting (FACS), as real-time probe working at near physiological concentrations, for performing transposon vector mutagenesis, and as a reporter for bacterial detection.

ADVANTAGE - (I) exhibits enhanced fluorescence relative to wild type **GFP**, when expressed in non-homologous cells at temperatures above 30 deg. C, and excited at 490 nm. (I) detects **GFP** reporters in mammalian cells at lower levels of expression with increased sensitivity relative to wild type **GFP**.

Dwg.0/7

ACCESSION NUMBER: 2003-095652 [09] WPIDS
DOC. NO. NON-CPI: N2003-075841
DOC. NO. CPI: C2003-024324

TITLE: Novel **fluorescent protein** derived from green **fluorescent protein** useful as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type green **fluorescent protein**.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): JONES, A E; MICHAEL, N P; STUBBS, S L J; THOMAS, N
PATENT ASSIGNEE(S): (AMSH) AMERSHAM BIOSCIENCES UK LTD; (AMSH) AMERSHAM PHARMACIA BIOTECH UK LTD; (JONE-I) JONES A E; (MICH-I) MICHAEL N P; (STUB-I) STUBBS S L J; (THOM-I) THOMAS N

COUNTRY COUNT: 98
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
GB 2374868	A	20021030	(200309)*		52
WO 2002085936	A1	20021031	(200309)	EN	

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO

RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
GB 2374868 B 20030709 (200353)
US 2003175859 A1 20030918 (200362)
EP 1381625 A1 20040121 (200410) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
RO SE SI TR

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
GB 2374868	A	GB 2001-23288	20010928
WO 2002085936	A1	WO 2001-GB4363	20010928
GB 2374868	B	GB 2001-23288	20010928
US 2003175859	A1	US 2001-967301	20010928
EP 1381625	A1	EP 2001-972260	20010928
		WO 2001-GB4363	20010928

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1381625	A1 Based on	WO 2002085936

PRIORITY APPLN. INFO: GB 2001-9858 20010423

=> d his

(FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004
L1 27483 S FLUORESCENT PROTEIN AND GFP
L2 16 S MODIFIED GFP AND WILDTYPE
L3 16 S L1 AND L2
L4 51 S L1 AND "S175"
L5 4 S L4 AND "F64"

=> s l4 and E222
'E222' NOT FOUND
The E# entered is not currently defined.

=> s l4 and "E222"
L6 2 L4 AND "E222"

=> s l1 and "S65"
L7 66 L1 AND "S65"

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 2 USPATFULL on STN
TI Fluorescent proteins
AB The present invention provides novel engineered derivatives of green **fluorescent protein** (**GFP**) which have an amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild type Green **Fluorescent Protein**. The modified GFPs exhibit enhanced fluorescence relative to wtGFP when expressed in non-homologous cells at temperatures above 30° C., and when excited at about 490 nm compared to the parent proteins, i.e. wtGFP. An example of a preferred protein is F64L-S175G-E222G-**GFP**. The modified GFPs provide a means for detecting **GFP** reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to

wtGFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:251073 USPATFULL
TITLE:	Fluorescent proteins
INVENTOR(S):	Stubbs, Simon Lawrence John, Amersham Buckinghamshire, UNITED KINGDOM Jones, Anne Elizabeth, Amersham Buckinghamshire, UNITED KINGDOM Michael, Nigel Paul, Amersham Buckinghamshire, UNITED KINGDOM Thomas, Nicholas, Amersham Buckinghamshire, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003175859	A1	20030918	
APPLICATION INFO.:	US 2001-967301	A1	20010928	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-9858	20010423

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	AMERSHAM BIOSCIENCES, PATENT DEPARTMENT, 800 CENTENNIAL AVENUE, PISCATAWAY, NJ, 08855
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	7 Drawing Page(s)
LINE COUNT:	1284

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Novel **fluorescent protein** derived from green **fluorescent protein** useful as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type green **fluorescent protein**.

AN 2003-095652 [09] WPIDS

AB GB 2374868 A UPAB: 20030206

NOVELTY - A **fluorescent protein** (I) derived from green **fluorescent protein** (**GFP**) or any functional **GFP** analog, has an amino acid sequence which is modified by amino acid substitution at position F64, at position S65 or **E222**, and at position **S175** compared with the amino acid sequence of wild-type **GFP**, and has different excitation spectrum and/or emission spectrum compared with wild-type **GFP**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a fusion compound (II) comprising a protein of interest fused to (I);

(2) a nucleic acid molecule (III) comprising a nucleotide sequence encoding (I) or (II);

(3) an expression vector (IV) comprising suitable expression control sequences operably linked to (III); and

(4) a host cell (V) transformed or transfected with a DNA construct comprising (IV).

USE - (III) is useful for measuring the expression of a protein of interest in a cell, by introducing (III) into a cell, where (III) is operably linked to and under the control of an expression control sequence which moderates expression of the protein of interest, culturing the cell under conditions suitable for the expression of the protein of interest, and detecting the fluorescence emission of **GFP** or functional **GFP** analog. (III) is useful for determining the cellular and/or

extracellular localization of a protein of interest. (III) is also useful for comparing the effect of one or more test substance(s) on the expression and/or localization of one or more different protein(s) of interest in a cell. The method involves:

(a) introducing into a cell, (III) operably linked to and under the control of a first expression control sequence and optionally fused to a nucleotide sequence encoding a fusion protein of interest, and optionally, at least one different nucleic acid molecule encoding a protein reporter molecule fused to a different protein of interest, where the nucleic acid molecule is operably linked to and under the control of a second expression control sequence, and the protein reporter molecule has or is capable of generating an emission signal which is spectrally distinct from that of **GFP** or functional **GFP** analog;

(b) culturing the cells under conditions suitable for the expression of the protein(s) of interest in the presence and absence of the test substance(s);

(c) determining the expression and/or localization of the protein(s) in the cells by detecting the fluorescence emission by optical means; and

(d) comparing the fluorescence emission obtained in the presence and absence of the test substance(s).

The samples of the cells in a fluid medium are introduced into separate vessels for each of the test substances to be studied (all claimed).

(I) is useful as a non-toxic marker for selection of transfected cells, as a protein label in living and fixed cells, as a marker in cell or organelle fusion, for visualizing translocation of intracellular proteins to a specific organelle, as a secretion marker, as genetic reporter or protein tag for protein and gene expression in transgenic animals, as a cell or organelle integrity marker, as a transfection marker, as a marker to be used in combination with fluorescent activated cell sorting (FACS), as real-time probe working at near physiological concentrations, for performing transposon vector mutagenesis, and as a reporter for bacterial detection.

ADVANTAGE - (I) exhibits enhanced fluorescence relative to wild type **GFP**, when expressed in non-homologous cells at temperatures above 30 deg. C, and excited at 490 nm. (I) detects **GFP** reporters in mammalian cells at lower levels of expression with increased sensitivity relative to wild type **GFP**.

Dwg.0/7

ACCESSION NUMBER: 2003-095652 [09] WPIDS
DOC. NO. NON-CPI: N2003-075841
DOC. NO. CPI: C2003-024324

TITLE: Novel **fluorescent protein** derived from green **fluorescent protein** useful as a transfection marker, has different excitation spectrum and/or emission spectrum compared with wild-type green **fluorescent protein**.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): JONES, A E; MICHAEL, N P; STUBBS, S L J; THOMAS, N
PATENT ASSIGNEE(S): (AMSH) AMERSHAM BIOSCIENCES UK LTD; (AMSH) AMERSHAM PHARMACIA BIOTECH UK LTD; (JONE-I) JONES A E; (MICH-I) MICHAEL N P; (STUB-I) STUBBS S L J; (THOM-I) THOMAS N

COUNTRY COUNT: 98
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
GB 2374868	A	20021030	(200309)*		52
WO 2002085936	A1	20021031	(200309)	EN	

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO

RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
GB 2374868 B 20030709 (200353)
US 2003175859 A1 20030918 (200362)
EP 1381625 A1 20040121 (200410) EN
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
GB 2374868	A	GB 2001-23288	20010928
WO 2002085936	A1	WO 2001-GB4363	20010928
GB 2374868	B	GB 2001-23288	20010928
US 2003175859	A1	US 2001-967301	20010928
EP 1381625	A1	EP 2001-972260	20010928
		WO 2001-GB4363	20010928

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1381625	A1 Based on	WO 2002085936

PRIORITY APPLN. INFO: GB 2001-9858 20010423

=> d his

(FILE 'HOME' ENTERED AT 14:46:22 ON 26 MAR 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, BIOSIS' ENTERED AT 14:46:40 ON 26 MAR 2004
L1 27483 S FLUORESCENT PROTEIN AND GFP
L2 16 S MODIFIED GFP AND WILDTYPE
L3 16 S L1 AND L2
L4 51 S L1 AND "S175"
L5 4 S L4 AND "F64"
L6 2 S L4 AND "E222"
L7 66 S L1 AND "S65"

=> d l7 ti abs ibib 1-10

L7 ANSWER 1 OF 66 MEDLINE on STN
TI The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process.
AB The extracellular N terminus of the endothelin B (ET(B)) receptor is susceptible to limited proteolysis (cleavage at R64 downward arrow **S65**), but the regulation and the functional consequences of the proteolysis remain elusive. We analyzed the ET(B) receptor or an ET(B)-**GFP** fusion protein stably or transiently expressed in HEK293 cells. After incubation of cells at 4 degrees C, only the full-length ET(B) receptor was detected at the cell surface. However, when cells were incubated at 37 degrees C, N-terminal cleavage was observed, provided endothelin 1 was present during the incubation. Cleavage was not inhibited by internalization inhibitors (sucrose, phenylarsine oxide). However, in cells incubated with both internalization inhibitors and metalloprotease inhibitors (batimastat, inhibitor of TNFalpha-convertase) or metal chelators (EDTA, phenanthroline), the cleavage was blocked, indicating that metalloproteases cleave the agonist-occupied ET(B) receptor at the cell surface. Functional analysis of a mutant ET(B) receptor lacking the first 64 amino acids ([Delta2-64]ET(B) receptor) revealed normal functional properties, but a 15-fold reduced cell surface expression. The results suggest a role of the N-terminal proteolysis in

the regulation of cell surface expression of the ET(B) receptor. This is the first example of a multispanning membrane protein, which is cleaved by a metalloprotease, but retains its functional activity and overall structure.

ACCESSION NUMBER: 2002684360 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12226103
TITLE: The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process.
AUTHOR: Grantcharova Evelina; Furkert Jens; Reusch H Peter; Krell Hans-Willi; Papsdorf Gisela; Beyermann Michael; Schulein Ralf; Rosenthal Walter; Oksche Alexander
CORPORATE SOURCE: Forschungsinstitut fur Molekulare Pharmakologie, Campus Berlin Buch, Robert-Roessle-Strasse 10, 13125 Berlin, Federal Republic of Germany.
SOURCE: Journal of biological chemistry, (2002 Nov 15) 277 (46) 43933-41.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200301
ENTRY DATE: Entered STN: 20021214
Last Updated on STN: 20030103
Entered Medline: 20030102

L7 ANSWER 2 OF 66 USPATFULL on STN
TI Human kinases
AB The invention provides human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonist. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

ACCESSION NUMBER: 2004:76648 USPATFULL
TITLE: Human kinases
INVENTOR(S): Yang, Junming, San Jose, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Buford, Neil, Durham, CT, UNITED STATES
Au-Young, Janice, Brisbane, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Reddy, Roopa, Sunnyvale, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Lal, Preeti, Santa Clara, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004058426	A1	20040325	
APPLICATION INFO.:	US 2002-168582	A1	20020620	(10)
	WO 2000-US35304		20001220	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 6360

L7 ANSWER 3 OF 66 USPATFULL on STN
TI Enzymes involved in glycoprotein and glycolipid metabolism
AB The invention provides human enzymes involved in glycoprotein and

glycolipid metabolism (GLYCOS) and polynucleotides which identify and encode GLYCOS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorder associated with aberrant expression of GLYCOS.

ACCESSION NUMBER: 2004:70606 USPATFULL
TITLE: Enzymes involved in glycoprotein and glycolipid metabolism
INVENTOR(S): Lal, Preeti G, Santa Clara, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Gandhi, Ameena R., San Francisco, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004053834	A1	20040318	
APPLICATION INFO.:	US 2003-415186	A1	20030423	(10)
	WO 2001-US44973		20011030	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
LINE COUNT: 4821

L7 ANSWER 4 OF 66 USPATFULL on STN
TI Human kinases
AB The invention provides human human kinases (PKIN) and polynucleotides which identify and encode PKIN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PKIN.

ACCESSION NUMBER: 2004:70167 USPATFULL
TITLE: Human kinases
INVENTOR(S): Gururajan, Rajagopal, SAN JOSE, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Yao, Monique G, Carmel, INDIA
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Bandman, Olga, Mountain View, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Recipon, Shirley A, San Francisco, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Borowsky, Mark L, Northampton, MA, UNITED STATES
Thornton, Michael B, Oakland, CA, UNITED STATES

Swarnakar, Anita, San Francisco, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004053394	A1	20040318	
APPLICATION INFO.:	US 2003-415011	A1	20030418	(10)
	WO 2001-US47728		20011020	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 99
EXEMPLARY CLAIM: 1
LINE COUNT: 9902

L7 ANSWER 5 OF 66 USPATFULL on STN
TI Novel metalloprotease polypeptide, MP-1
AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

ACCESSION NUMBER: 2004:63784 USPATFULL
TITLE: Novel metalloprotease polypeptide, MP-1
INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004048302	A1	20040311	
APPLICATION INFO.:	US 2003-651722	A1	20030829	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED, Pat. No. US 6642041			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266518P	20010205 (60)
	US 2001-282814P	20010410 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 43 Drawing Page(s)
LINE COUNT: 15444

L7 ANSWER 6 OF 66 USPATFULL on STN
TI Lipid metabolism enzymes
AB The invention provides human lipid metabolism enzymes (LMM) and polynucleotides which identify and encode LMM. The invention also provides expression vectors, host cells, antibodies, agonists, and

antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LMM.

ACCESSION NUMBER: 2004:63751 USPATFULL
TITLE: Lipid metabolism enzymes
INVENTOR(S): Griffin, Jennifer A, Fremont, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Ammena R, Gandhi, San Francisco, CA, UNITED STATES
Lu, Yan, Palo Alto, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Hafalia, April J A, Santa Clara, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Das, Debopriya, Mountain View, CA, UNITED STATES
Thornton, Michael B, Woodside, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004048269	A1	20040311	
APPLICATION INFO.:	US 2003-362628	A1	20030221	(10)
	WO 2001-US26365		20010822	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 5637

L7 ANSWER 7 OF 66 USPATFULL on STN
TI Extracellular signaling molecules
AB The invention provides human extracellular signaling molecules (EXCS) and polynucleotides which identify and encode EXCS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of EXCS.

ACCESSION NUMBER: 2004:63726 USPATFULL
TITLE: Extracellular signaling molecules
INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Lal, Preeti, Santa Clara, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Bandman, Olga, Mountain View, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Azimzai, Yalda, Castro Valley, CA, UNITED STATES
Lu, Dyung Aina M., San Jose, CA, UNITED STATES
Arvizu, Chandra, Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004048244	A1	20040311	
APPLICATION INFO.:	US 2001-969984	A1	20011002	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 107
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 5730

L7 ANSWER 8 OF 66 USPATFULL on STN
TI Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A
AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

ACCESSION NUMBER: 2004:57444 USPATFULL
TITLE: Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A
INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES
Zopf, David, Wayne, PA, UNITED STATES
Bayer, Robert, San Diego, CA, UNITED STATES
Bowe, Caryn, Doylestown, PA, UNITED STATES
Hakes, David, Willow Grove, PA, UNITED STATES
Chen, Xi, Lansdale, PA, UNITED STATES
PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043446	A1	20040304
APPLICATION INFO.:	US 2003-411037	A1	20030409 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-407527P	20020828 (60)
	US 2002-404249P	20020816 (60)
	US 2002-396594P	20020717 (60)
	US 2002-391777P	20020625 (60)
	US 2002-387292P	20020607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
NUMBER OF CLAIMS: 122
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 497 Drawing Page(s)
LINE COUNT: 19395

L7 ANSWER 9 OF 66 USPATFULL on STN
TI Polynucleotides encoding a novel metalloprotease, MP-1
AB The present invention provides novel polynucleotides encoding MP-1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel MP-1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:57405 USPATFULL
TITLE: Polynucleotides encoding a novel metalloprotease, MP-1
INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004043407	A1	20040304
APPLICATION INFO.:	US 2003-649273	A1	20030827 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED, Pat. No. US 6642041

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-266518P	20010205 (60)
	US 2001-282814P	20010410 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 66 USPATFULL on STN
TI Intracellular signaling molecules
AB The invention provides human intracellular signaling molecules (INTSIG) and polynucleotides which identify and encode INTSIG. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of INTSIG.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:57393 USPATFULL
TITLE: Intracellular signaling molecules
INVENTOR(S): Baughn, Mariah R, San Leandro, CA, UNITED STATES
Ding, Li, Creve Couer, MO, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Gururajan, Rajagopal, San Jose, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Kearney, Liam, San Francisco, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
M Lu, Dyung Aina, San Jose, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Thornton, Michael B, Oakland, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Warren, Bridget A, Encinitas, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2004043395	A1	20040304	
APPLICATION INFO.:	US 2003-399456	A1	20030414	(10)
	WO 2001-US32090		20011012	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	INCYTE CORPORATION, 3160 PORTER DRIVE, PALO ALTO, CA, 94304			
NUMBER OF CLAIMS:	95			
EXEMPLARY CLAIM:	1			
LINE COUNT:	6007			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.